Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer.

[1]  A. Harris,et al.  A reliable external control for ribonuclease protection assays. , 1997, Nucleic Acids Research.

[2]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[3]  D. Carbone,et al.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.

[4]  A. De Benedetti,et al.  Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: Implications for tumor angiogenesis , 1996, International journal of cancer.

[5]  A. Wilks,et al.  Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. , 1996, Cancer research.

[6]  D. Mukhopadhyay,et al.  Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. , 1995, Cancer research.

[7]  S. Groshen,et al.  Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. , 1995, Journal of the National Cancer Institute.

[8]  S. Fox,et al.  Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. , 1994, British journal of urology.

[9]  S C Chen,et al.  Accumulation of nuclear p53 and tumor progression in bladder cancer. , 1994, The New England journal of medicine.

[10]  W. Linehan,et al.  Suramin inhibits proliferation and DNA synthesis in transitional carcinoma cell lines. , 1994, The Journal of urology.

[11]  Erwin G. Van Meir,et al.  Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells , 1994, Nature Genetics.

[12]  W. Kolch,et al.  Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. , 1994, Oncogene.

[13]  N. Weidner,et al.  Intratumoral microvessel density and L53 protein: Correlation with metastasis in head‐and‐neck squamous‐cell carcinoma , 1993, International journal of cancer.

[14]  S. Groshen,et al.  p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. , 1993, The American journal of pathology.

[15]  R. Takahashi,et al.  Metachronous multifocal development of urothelial cancers by intraluminal seeding , 1993, The Lancet.

[16]  F. Sola,et al.  Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity. , 1992, British Journal of Cancer.

[17]  D. Connolly,et al.  Specific binding of vascular permeability factor to endothelial cells. , 1991, Biochemical and biophysical research communications.

[18]  A. De Benedetti,et al.  Overexpression of eukaryotic protein synthesis initiation factor 4E in HeLa cells results in aberrant growth and morphology. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[19]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[20]  A. Harris,et al.  Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer. , 1997, Cancer research.

[21]  R. Jain,et al.  During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. , 1996, Nature medicine.

[22]  D. Jodrell,et al.  Suramin, an active drug for prostate cancer: interim observations in a phase I trial. , 1993, Journal of the National Cancer Institute.

[23]  A. Harris,et al.  Cathepsin D levels in primary breast cancers: relationship with epidermal growth factor receptor, oestrogen receptor and axillary nodal status. , 1993, European journal of cancer.

[24]  J. Winer,et al.  The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. , 1992, Growth factors.